Category: MS Drug Therapies

PRESS RELEASE: Genentech Expands Its Multiple Sclerosis Portfolio With Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus (ocrelizumab)

September 8, 2020  Phase III clinical trial program initiated for investigational medicine fenebrutinib, designed to be a highly selective and…

Stuart Schlossman

Mavenclad Lowers MS Relapse Rates, Study Comparing …

Click HERE to Subscribe for the MS Beacon Newsletter Mavenclad (cladribine) appears to be better at lowering relapse rates during the…

Stuart Schlossman

LEMTRADA: Who is the Right Patient for this Multiple Sclerosis Drug?

vlog produced by Aaron Boster, MD Click HERE to Subscribe for the MS Beacon Newsletter Information Shared by: MSViewsandNews,  Visit our…

Stuart Schlossman

Launching a new MS drug responsibly, during Covid-19

Click HERE to Subscribe for the MS Beacon Newsletter  As a company, Novartis had to ask themselves what launching a…

Stuart Schlossman

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Click HERE to Subscribe for the MS Beacon Newsletter       East Hanover, August 20, 2020 — Novartis today announced that…

Stuart Schlossman

Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera®

Click HERE to Subscribe for the MS Beacon Newsletter HERTFORDSHIRE, England and PITTSBURGH, Aug. 19, 2020 /PRNewswire/ — Mylan N.V. (NASDAQ: MYL) today announced the launch of the…

Stuart Schlossman

Rituximab More Effective Than Gilenya, Tecfidera, and Comparable to Tysabri, Study Finds

AUGUST 11, 2020   BY MARTA FIGUEIREDO   Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod) and Tecfidera (dimethyl…

Stuart Schlossman

Jeffrey Cohen, MD: S1P Modulator Development in Multiple Sclerosis

Click HERE to Subscribe for the MS Beacon Newsletter “The hope was that by developing more selective S1P modulators, that…

Stuart Schlossman

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

August 5, 2020                 Drug Shows Promise in Preventing Multiple Sclerosis Relapses Ofatumumab is…

Stuart Schlossman

Innovations in MS Care and Treatment

Click HERE to Subscribe for the MS Beacon Newsletter Event Date: October 12, 2019 { a (3) Speaker presentation and…

Stuart Schlossman

Categories

Latest Blog Posts